Opinion|Videos|December 25, 2024
Treatment Goals for Patients With PBC
Panelists discuss how the main treatment goals for patients with primary biliary cholangitis (PBC) include improving liver biochemistry, preventing disease progression to cirrhosis, managing symptoms, and enhancing overall quality of life through regular monitoring and appropriate therapeutic interventions.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What are the primary treatment goals for patients with PBC?
Advertisement
Related to this article
Authors of a pharmacist-directed transitions of care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
An investigational glypican-3–directed CAR T-cell therapy engineered to express IL-15 and IL-21 produced a complete response lasting at least 1 year in a child with chemotherapy-resistant metastatic hepatoblastoma.
The investigational once-weekly dual GLP-1/GIP receptor agonist, engineered with signaling bias at both receptors, met both primary end points at 48 weeks.
Investigational antiamyloid monoclonal antibodies may offer a novel pathway to disease reversal.
Increasingly, pharmacists are leading the obesity management team.
HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.
A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.
A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Bridging the Gap: Pharmacist Experiences Obtaining DEA Licenses
2
Armored CAR T-Cell Therapy Produces Durable Complete Response in Pediatric Solid Tumors
3
Eight Names, One Drug: Why Adalimumab Biosimilars Are Creating Real Confusion at the Counter
4
Expert Q&A: Pharmacists Address Pneumococcal Vaccine Hesitancy and Screening Complexity in Transitions of Care
5